Abiopharma

Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases

Rapid Micro Biosystems Reports First Quarter 2025 Financial Results

Aclaris Therapeutics to Participate in the HC Wainwright“HCW@Home” Series

Kiora Pharmaceuticals Reports First Quarter Results; Initiating Two Phase 2 Trials for Treatment of Retinal Diseases; Cash and Short-term Investments Expected to Fund Operations into Late 2027

Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimers Patient Treated with Intranasal Foralumab

Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025

Kymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business Update

Castle Biosciences - Real-World Study Confirms Long-Term Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class Result

Real-World Study Confirms Long-Term Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class Result

InspireMD Reports First Quarter 2025 Financial Results